Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bionano Genomics, Inc. (BNGO)
USD1.18
+0.03 (+2.58%)
US NASDAQ Healthcare Medical - Diagnostics & Research
Address
9540 Towne Centre Drive 92121
San Diego, CA, US
San Diego, CA, US
CEO
Robert Erik Holmlin
Website
bionanogenomics.com
IPO
2018-08-21
CIK 1411690 ISIN US09075F4046
Also trades on
NASDAQ Capital Market · BNGO (USD)
NASDAQ Capital Market · BNGOW (USD)
Description
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.18
+0.03 (+2.58%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
151.7K
Beta
1.63
Float Shares
3.27M
Free Float %
99.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.79% | -6.67% | +6.78% | +14.55% | -14.29% | -17.65% | -68.10% | -99.68% | -99.95% | -97.95% | -97.95% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
1.18
Low
1.00
-15.2%
Consensus
46.50
+3,841.7%
Median
5.00
+323.8%
High
175.00
+14,734.3%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
8.00
+578.1%
|
| All Time | 5 |
107.20
+8,987.1%
|
Quality scores
Altman Z-Score
-14.35
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%-7.4% Q1'26: -99.9% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+94.5% ★ Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-82.3% Q1'26: -85,479.3% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-117.0% Q1'26: +0.0% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%-87.5% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+186.2% Q1'26: -100.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.29× Q1'26: -0.54× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
12.00M
est: 11.45M (+4.8%)
|
10.13M
est: 11.76M (-13.9%)
|
8.50M
est: 8.00M (+6.2%)
|
17.98M
est: 17.26M (+4.2%)
|
27.80M
est: 27.69M (+0.4%)
|
36.12M
est: 36.58M (-1.3%)
|
30.78M
est: 28.80M (+6.9%)
|
28.51M
est: 28.44M (+0.2%)
|
32.14M
32.04M – 32.24M
+13.0% YoY
|
43.30M
43.16M – 43.44M
+34.7% YoY
|
54.27M
54.27M – 54.27M
+25.3% YoY
|
65.98M
65.77M – 66.19M
+21.6% YoY
|
80.15M
79.90M – 80.40M
+21.5% YoY
|
| EBITDA |
-15.78M
est: -11.45M (-37.8%)
|
-26.38M
est: -11.76M (-124.3%)
|
-35.57M
est: -8.00M (-344.5%)
|
-73.86M
est: -17.26M (-328.0%)
|
-120.32M
est: -27.69M (-334.6%)
|
-213.60M
est: -35.32M (-504.7%)
|
-97.47M
est: -27.81M (-250.5%)
|
-23.61M
est: -27.46M (+14.0%)
|
-31.03M
-31.13M – -30.93M
-13.0% YoY
|
-41.81M
-41.94M – -41.68M
-34.7% YoY
|
-52.41M
-52.41M – -52.41M
-25.3% YoY
|
-63.71M
-63.91M – -63.51M
-21.6% YoY
|
-77.40M
-77.64M – -77.15M
-21.5% YoY
|
| EBIT |
-17.10M
est: -11.45M (-49.3%)
|
-27.51M
est: -11.76M (-133.9%)
|
-37.05M
est: -8.00M (-363.0%)
|
-77.23M
est: -17.26M (-347.5%)
|
-130.41M
est: -27.69M (-371.1%)
|
-227.31M
est: -36.58M (-521.4%)
|
-111.70M
est: -28.80M (-287.8%)
|
-33.34M
est: -28.44M (-17.2%)
|
-32.14M
-32.24M – -32.04M
-13.0% YoY
|
-43.30M
-43.44M – -43.16M
-34.7% YoY
|
-54.27M
-54.27M – -54.27M
-25.3% YoY
|
-65.98M
-66.19M – -65.77M
-21.6% YoY
|
-80.15M
-80.40M – -79.90M
-21.5% YoY
|
| Net Income |
-18.50M
est: -2.60B (+99.3%)
|
-29.82M
est: -2.32B (+98.7%)
|
-41.11M
est: -456.65M (+91.0%)
|
-72.44M
est: -283.27M (+74.4%)
|
-132.60M
est: -488.09M (+72.8%)
|
-232.49M
est: -22.77M (-921.1%)
|
-112.02M
est: -436.14M (+74.3%)
|
-26.40M
est: -34.82M (+24.2%)
|
-14.16M
-14.21M – -14.10M
+59.3% YoY
|
-6.04M
-6.07M – -6.02M
+57.3% YoY
|
-3.21M
-3.23M – -3.20M
+46.8% YoY
|
-1.52M
-1.53M – -1.52M
+52.5% YoY
|
1.14M
1.14M – 1.15M
+175.0% YoY
|
| SGA |
14.22M
est: 24.64M (-42.3%)
|
20.16M
est: 25.30M (-20.3%)
|
—
est: 17.21M (-100.0%)
|
58.49M
est: 37.12M (+57.6%)
|
88.60M
est: 59.54M (+48.8%)
|
94.96M
est: 87.69M (+8.3%)
|
51.86M
est: 69.04M (-24.9%)
|
35.15M
est: 68.18M (-48.4%)
|
77.04M
76.80M – 77.29M
+13.0% YoY
|
103.81M
103.48M – 104.13M
+34.7% YoY
|
130.12M
130.12M – 130.12M
+25.3% YoY
|
158.18M
157.69M – 158.68M
+21.6% YoY
|
192.15M
191.55M – 192.75M
+21.5% YoY
|
| EPS |
-94,089.60
est: -1,365.00 (-6,793.0%)
|
-71,662.20
est: -1,218.00 (-5,783.6%)
|
-14,194.80
est: -240.00 (-5,814.5%)
|
-157.02
est: -148.88 (-5.5%)
|
-267.71
est: -256.52 (-4.4%)
|
-408.48
est: -4.18 (-9,668.6%)
|
-88.13
est: -80.10 (-10.0%)
|
-4.85
est: -6.40 (+24.2%)
|
-2.60
-2.61 – -2.59
+59.3% YoY
|
-1.11
-1.11 – -1.11
+57.3% YoY
|
-0.59
-0.59 – -0.59
+46.8% YoY
|
-0.28
-0.28 – -0.28
+52.5% YoY
|
0.21
0.21 – 0.21
+175.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-18.26M
OE per share TTM
-4.72
Owner's Yield
-266.11%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
84.3%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
10
Total invested
553.7K
Insider transactions (90d)
0
Beneficial owners (>5%)
10
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 18.66M | 6.50% | 18.34M | — | 18.66M | — | HC | Delaware | 2022-02-04 | ↗ |
| 2 | The Vanguard Group - 23-1945930 | 14.83M | 5.13% | — | — | — | 761.0K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 3 | WEALTH STRATEGY HOLDING LIMITED | 1.95M | 15.13% | 1.95M | — | 1.95M | — | FI | HONG KONG SAR | 2018-12-27 | ↗ |
| 4 | Hudson Bay Capital Management LP | 1.92M | 1.24% | — | 1.92M | — | — | PN | State of Delaware | 2021-02-09 | ↗ |
| 5 | Sander Gerber | 1.92M | 1.24% | — | 1.92M | — | — | IN | United States | 2021-02-09 | ↗ |
| 6 | Sio Capital Management, LLC 20-4586565 | 1.21M | 4.57% | — | 1.21M | — | 1.21M | IA | — | 2020-02-14 | ↗ |
| 7 | 27-4413262 | 576.4K | 6.10% | 576.4K | — | 576.4K | — | OO | Maryland | 2018-10-05 | ↗ |
| 8 | DP VIII Associates, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2021-01-21 | ↗ |
| 9 | Domain Partners VIII, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2021-01-21 | ↗ |
| 10 | Identification Nos. of above persons (. | — | 0.00% | — | — | — | — | OO | Delaware | 2018-10-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
10
-20 vs prev Q
New positions
4
Closed positions
24
Increased
7
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | GSA CAPITAL PARTNERS LLP | 337.8K +337.8K (+100.0%) | 517.0K +517.0K (+100.0%) | 6.33% +6.328 pp | 0.04% +0.045 pp | USD1.53 +0.0% | 3 qtrs — |
| 2 | DRW SECURITIES, LLC | 168.5K +168.5K (+100.0%) | 257.7K +257.7K (+100.0%) | 3.16% +3.156 pp | 0.01% +0.007 pp | USD1.53 +0.0% | 1 qtrs NEW |
| 3 | VANGUARD GROUP INC | 82.3K +31.8K (+63.1%) | 125.9K +39.6K (+45.9%) | 1.54% +0.076 pp | 0.00% +0.000 pp | USD1.64 -6.7% | 4 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 66.8K +39.9K (+148.8%) | 102.2K +56.3K (+122.6%) | 1.25% +0.471 pp | 0.00% +0.000 pp | USD1.93 -20.7% | 4 qtrs — |
| 5 | CARRET ASSET MANAGEMENT, LLC | 44.1K +19.1K (+76.4%) | 67.5K +24.7K (+57.8%) | 0.83% +0.100 pp | 0.01% +0.002 pp | USD1.63 -6.1% | 2 qtrs — |
| 6 | TWO SIGMA INVESTMENTS, LP | 40.5K +40.5K (+100.0%) | 62.0K +62.0K (+100.0%) | 0.76% +0.759 pp | 0.00% +0.000 pp | USD1.53 +0.0% | 1 qtrs NEW |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 37.0K +37.0K (+100.0%) | 56.6K +56.6K (+100.0%) | 0.69% +0.693 pp | 0.00% +0.000 pp | USD1.53 +0.0% | 1 qtrs NEW |
| 8 | JANE STREET GROUP, LLC | 22.2K +22.2K (+100.0%) | 33.9K +33.9K (+100.0%) | 0.42% +0.415 pp | 0.00% +0.000 pp | USD1.53 +0.0% | 1 qtrs NEW |
| 9 | NORTHERN TRUST CORP | 20.5K +20.5K (+100.0%) | 31.4K +31.4K (+100.0%) | 0.38% +0.384 pp | 0.00% +0.000 pp | USD1.53 +0.0% | 1 qtrs NEW |
| 10 | R SQUARED LTD | 13.8K +13.8K (+100.0%) | 21.1K +21.1K (+100.0%) | 0.26% +0.258 pp | 0.01% +0.010 pp | USD1.53 +0.0% | 1 qtrs NEW |
| 11 | ENGINEERS GATE MANAGER LP | 10.2K +10.2K (+100.0%) | 15.6K +15.6K (+100.0%) | 0.19% +0.191 pp | 0.00% +0.000 pp | USD1.53 +0.0% | 1 qtrs NEW |
| 12 | BLACKROCK, INC. | 9.9K +— (+0.0%) | 15.2K -1.8K (-10.5%) | 0.19% -0.103 pp | 0.00% +0.000 pp | USD2.79 -45.2% | 4 qtrs — |
| 13 | UBS GROUP AG | 9.1K -54.8K (-85.8%) | 13.9K -95.4K (-87.3%) | 0.17% -1.687 pp | 0.00% +0.000 pp | USD1.76 -13.1% | 4 qtrs — |
| 14 | BANK OF AMERICA CORP /DE/ | 8.5K -54.0 (-0.6%) | 12.9K -1.6K (-11.1%) | 0.16% -0.089 pp | 0.00% +0.000 pp | USD2.78 -45.0% | 4 qtrs — |
| 15 | ADVISOR GROUP HOLDINGS, INC. | 5.7K +1.5K (+36.6%) | 8.8K +1.5K (+21.2%) | 0.11% -0.015 pp | 0.00% +0.000 pp | USD2.26 -32.3% | 4 qtrs — |
| 16 | TOWER RESEARCH CAPITAL LLC (TRC) | 3.5K +3.5K (+14,084.0%) | 5.4K +5.4K (+12,516.3%) | 0.07% +0.066 pp | 0.00% +0.000 pp | USD1.54 -0.6% | 3 qtrs — |
| 17 | MORGAN STANLEY | 2.2K -4.0K (-64.2%) | 3.4K -7.2K (-67.9%) | 0.04% -0.139 pp | 0.00% +0.000 pp | USD2.79 -45.2% | 4 qtrs — |
| 18 | GROUP ONE TRADING, L.P. | 1.3K -46.0 (-3.4%) | 2.0K -315.0 (-13.6%) | 0.02% -0.015 pp | 0.00% +0.000 pp | USD2.79 -45.2% | 4 qtrs — |
| 19 | CONCORD WEALTH PARTNERS | 1.0K +— (+0.0%) | 1.5K -180.0 (-10.5%) | 0.02% -0.010 pp | 0.00% +0.000 pp | USD1.71 -10.5% | 2 qtrs — |
| 20 | SBI SECURITIES CO., LTD. | 224.00 -10.0 (-4.3%) | 343.00 -57.0 (-14.3%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD0.49 +212.2% | 5 qtrs — |
| 21 | WELLS FARGO & COMPANY/MN | 30.00 -83.0 (-73.5%) | 46.00 -147.0 (-76.2%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD2.77 -44.8% | 4 qtrs — |
| 22 | BNP PARIBAS ARBITRAGE, SNC | 13.00 +— (+0.0%) | 20.00 -2.0 (-9.1%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.15 -51.4% | 4 qtrs — |
| 23 | JPMORGAN CHASE & CO | 11.00 +— (+0.0%) | 17.00 -2.0 (-10.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.73 -44.0% | 4 qtrs — |
| 24 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 8.00 -1.0 (-11.1%) | 12.00 -3.0 (-20.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.63 -41.8% | 4 qtrs — |
| 25 | ALLWORTH FINANCIAL LP | 6.00 +— (+0.0%) | 10.00 -1.0 (-9.1%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.67 -42.7% | 4 qtrs — |
| 26 | TD WATERHOUSE CANADA INC. | 4.00 +— (+0.0%) | 6.00 -1.0 (-14.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.75 -44.4% | 4 qtrs — |
| 27 | ACTIVEST WEALTH MANAGEMENT | 3.00 +— (+0.0%) | 5.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.67 -42.7% | 4 qtrs — |
| 28 | NATIONAL BANK OF CANADA /FI/ | 2.00 +2.0 (+100.0%) | 3.00 +3.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.50 +2.0% | 1 qtrs NEW |
| 29 | AVISO FINANCIAL INC. | 1.00 +— (+0.0%) | 1.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 -23.5% | 4 qtrs — |
| 30 | JONES FINANCIAL COMPANIES LLLP | — -2.0 (-100.0%) | — -3.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 31 | HRT FINANCIAL LP | — -20.3K (-100.0%) | — -34.0K (-100.0%) | 0.00% -0.591 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 32 | GPS WEALTH STRATEGIES GROUP, LLC | — -16.0 (-100.0%) | — -27.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 33 | TWO SIGMA SECURITIES, LLC | — -15.6K (-100.0%) | — -26.6K (-100.0%) | 0.00% -0.453 pp | 0.00% -0.004 pp | USD— | 2 qtrs SOLD |
| 34 | FIFTH THIRD BANCORP | — -1.0 (-100.0%) | — -2.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 35 | FARTHER FINANCE ADVISORS, LLC | — -158.0 (-100.0%) | — -270.0 (-100.0%) | 0.00% -0.005 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 36 | WEALTHSPIRE ADVISORS, LLC | — -2.0 (-100.0%) | — -4.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 37 | STIFEL FINANCIAL CORP | — -10.5K (-100.0%) | — -18.0K (-100.0%) | 0.00% -0.306 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 99.9K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
3.00
Bullish
Buys
5
Sells
5
Shares acquired
162.0K
Shares disposed
98.00
Cash buys
—
Cash sales
—
Net activity
+161,867
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-17 | OLDAKOWSKI MARK | Officer | F-InKind | D | Common Stock | 20 | 1.10 | 22.00 | 895 | D | ↗ |
| 2026-02-17 | Holmlin R. Erik | Director / Officer | F-InKind | D | Common Stock | 51 | 1.10 | 56.10 | 1,657 | D | ↗ |
| 2026-02-17 | Dixon Jonathan V. | Officer | F-InKind | D | Common Stock | 6 | 1.10 | 6.60 | 263 | D | ↗ |
| 2026-02-17 | Chaubey Alka | Officer | F-InKind | D | Common Stock | 18 | 1.10 | 19.80 | 644 | D | ↗ |
| 2026-02-17 | Adamchak Mark | Officer | F-InKind | D | Common Stock | 3 | 1.10 | 3.30 | 260 | D | ↗ |
| 2026-02-02 | OLDAKOWSKI MARK | Officer | A-Award | A | Stock Option (Right to Buy) | 27,737 | 1.27 | 35.2K | 27,737 | D | ↗ |
| 2026-02-02 | Holmlin R. Erik | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 69,484 | 1.27 | 88.2K | 69,484 | D | ↗ |
| 2026-02-02 | Dixon Jonathan V. | Officer | A-Award | A | Stock Option (Right to Buy) | 26,117 | 1.27 | 33.2K | 26,117 | D | ↗ |
| 2026-02-02 | Chaubey Alka | Officer | A-Award | A | Stock Option (Right to Buy) | 27,737 | 1.27 | 35.2K | 27,737 | D | ↗ |
| 2026-02-02 | Adamchak Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 10,890 | 1.27 | 13.8K | 10,890 | D | ↗ |
| 2025-09-11 | OLDAKOWSKI MARK | Officer | F-InKind | D | Common Stock | 59 | 4.06 | 239.54 | 915 | D | ↗ |
| 2025-09-11 | Chaubey Alka | Officer | F-InKind | D | Common Stock | 51 | 4.06 | 207.06 | 662 | D | ↗ |
| 2025-06-11 | Vuori Kristiina MD | Director | A-Award | A | Stock Option (Right to Buy) | 2,775 | 3.67 | 10.2K | 2,775 | D | ↗ |
| 2025-06-11 | TWOMEY CHRISTOPHER J | Director | A-Award | A | Stock Option (Right to Buy) | 2,775 | 3.67 | 10.2K | 2,775 | D | ↗ |
| 2025-06-11 | Rajkovic Aleksandar | Director | A-Award | A | Stock Option (Right to Buy) | 2,775 | 3.67 | 10.2K | 2,775 | D | ↗ |
| 2025-06-11 | Mamuszka Hannah | Director | A-Award | A | Stock Option (Right to Buy) | 2,775 | 3.67 | 10.2K | 2,775 | D | ↗ |
| 2025-06-11 | Luderer Albert | Director | A-Award | A | Stock Option (Right to Buy) | 2,775 | 3.67 | 10.2K | 2,775 | D | ↗ |
| 2025-06-11 | Linney Yvonne | Director | A-Award | A | Stock Option (Right to Buy) | 2,775 | 3.67 | 10.2K | 2,775 | D | ↗ |
| 2025-06-11 | BARKER DAVID L | Director | A-Award | A | Stock Option (Right to Buy) | 2,775 | 3.67 | 10.2K | 2,775 | D | ↗ |
| 2025-06-03 | OLDAKOWSKI MARK | Officer | F-InKind | D | Common Stock | 27 | 3.69 | 99.63 | 974 | D | ↗ |
| 2025-06-03 | Holmlin R. Erik | Director / Officer | F-InKind | D | Common Stock | 75 | 3.69 | 276.75 | 1,708 | D | ↗ |
| 2025-06-03 | Dixon Jonathan V. | Officer | F-InKind | D | Common Stock | 25 | 3.69 | 92.25 | 269 | D | ↗ |
| 2025-06-03 | Chaubey Alka | Officer | F-InKind | D | Common Stock | 24 | 3.69 | 88.56 | 713 | D | ↗ |
| 2025-06-03 | Adamchak Mark | Officer | F-InKind | D | Common Stock | 7 | 3.69 | 25.83 | 263 | D | ↗ |
| 2025-03-14 | OLDAKOWSKI MARK | Officer | A-Award | A | Stock Option (Right to Buy) | 6,966 | 3.47 | 24.2K | 6,966 | D | ↗ |
| 2025-03-14 | Holmlin R. Erik | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 17,449 | 3.47 | 60.5K | 17,449 | D | ↗ |
| 2025-03-14 | Dixon Jonathan V. | Officer | A-Award | A | Stock Option (Right to Buy) | 6,559 | 3.47 | 22.8K | 6,559 | D | ↗ |
| 2025-03-14 | Chaubey Alka | Officer | A-Award | A | Stock Option (Right to Buy) | 6,966 | 3.47 | 24.2K | 6,966 | D | ↗ |
| 2025-03-14 | Adamchak Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 3,029 | 3.47 | 10.5K | 3,029 | D | ↗ |
| 2025-02-15 | OLDAKOWSKI MARK | Officer | F-InKind | D | Common Stock | 20 | 5.73 | 114.60 | 1,001 | D | ↗ |
| 2025-02-15 | Holmlin R. Erik | Director / Officer | F-InKind | D | Common Stock | 51 | 5.73 | 292.23 | 1,981 | D | ↗ |
| 2025-02-15 | Dixon Jonathan V. | Officer | F-InKind | D | Common Stock | 6 | 5.73 | 34.38 | 294 | D | ↗ |
| 2025-02-15 | Chaubey Alka | Officer | F-InKind | D | Common Stock | 18 | 5.73 | 103.14 | 737 | D | ↗ |
| 2025-02-15 | Adamchak Mark | Officer | F-InKind | D | Common Stock | 4 | 5.73 | 22.92 | 270 | D | ↗ |
| 2024-10-01 | Adamchak Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 17,500 | 0.42 | 7.4K | 17,500 | D | ↗ |
| 2024-09-18 | Adamchak Mark | Officer | — | — | Stock Option (Right to Buy) | 753 | 10.40 | 7.8K | 0 | D | ↗ |
| 2024-09-11 | OLDAKOWSKI MARK | Officer | F-InKind | D | Common Stock | 3,568 | 0.48 | 1.7K | 61,283 | — | ↗ |
| 2024-09-11 | Chaubey Alka | Officer | F-InKind | D | Common Stock | 3,075 | 0.48 | 1.5K | 45,323 | — | ↗ |
| 2024-06-18 | Wong Vincent Jung-Fai | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.78 | 23.3K | 30,000 | — | ↗ |
| 2024-06-18 | Vuori Kristiina MD | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.78 | 23.3K | 30,000 | — | ↗ |
| 2024-06-18 | TWOMEY CHRISTOPHER J | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.78 | 23.3K | 30,000 | — | ↗ |
| 2024-06-18 | Rajkovic Aleksandar | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.78 | 23.3K | 30,000 | — | ↗ |
| 2024-06-18 | Mamuszka Hannah | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.78 | 23.3K | 30,000 | — | ↗ |
| 2024-06-18 | Luderer Albert | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.78 | 23.3K | 30,000 | — | ↗ |
| 2024-06-18 | Linney Yvonne | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.78 | 23.3K | 30,000 | — | ↗ |
| 2024-06-18 | BARKER DAVID L | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.78 | 23.3K | 30,000 | — | ↗ |
| 2024-06-03 | OLDAKOWSKI MARK | Officer | A-Award | A | Common Stock | 16,000 | 0.00 | — | 64,698 | — | ↗ |
| 2024-06-03 | Kama Gulsen | Officer | A-Award | A | Common Stock | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2024-06-03 | Holmlin R. Erik | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 204,000 | 0.93 | 189.7K | 204,000 | — | ↗ |
| 2024-06-03 | Dixon Jonathan V. | Officer | A-Award | A | Common Stock | 14,500 | 0.00 | — | 18,025 | — | ↗ |
| 2024-06-03 | Chaubey Alka | Officer | A-Award | A | Common Stock | 16,000 | 0.00 | — | 48,245 | — | ↗ |
| 2024-02-15 | OLDAKOWSKI MARK | Officer | F-InKind | D | Common Stock | 1,229 | 1.27 | 1.6K | 48,644 | — | ↗ |
| 2024-02-15 | Holmlin R. Erik | Director / Officer | F-InKind | D | Common Stock | 3,073 | 1.27 | 3.9K | 77,663 | — | ↗ |
| 2024-02-15 | Dixon Jonathan V. | Officer | F-InKind | D | Common Stock | 402 | 1.27 | 510.54 | 3,525 | — | ↗ |
| 2024-02-15 | Chaubey Alka | Officer | F-InKind | D | Common Stock | 1,081 | 1.27 | 1.4K | 31,487 | — | ↗ |
| 2023-09-18 | OLDAKOWSKI MARK | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.00 | 120.0K | 40,000 | — | ↗ |
| 2023-09-18 | Kama Gulsen | Officer | A-Award | A | Stock Option (Right to Buy) | 106,000 | 3.00 | 318.0K | 106,000 | — | ↗ |
| 2023-09-18 | Chaubey Alka | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 144,794 | — | ↗ |
| 2023-09-11 | Kama Gulsen | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-14 | Wong Vincent Jung-Fai | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.75 | 186.5K | 250,000 | — | ↗ |
| 2023-06-14 | Vuori Kristiina MD | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.75 | 186.5K | 250,000 | — | ↗ |
| 2023-06-14 | TWOMEY CHRISTOPHER J | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.75 | 186.5K | 250,000 | — | ↗ |
| 2023-06-14 | Rajkovic Aleksandar | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.75 | 186.5K | 250,000 | — | ↗ |
| 2023-06-14 | Mamuszka Hannah | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.75 | 186.5K | 250,000 | — | ↗ |
| 2023-06-14 | Luderer Albert | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.75 | 186.5K | 250,000 | — | ↗ |
| 2023-06-14 | Linney Yvonne | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.75 | 186.5K | 250,000 | — | ↗ |
| 2023-06-14 | BARKER DAVID L | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.75 | 186.5K | 250,000 | — | ↗ |
| 2023-06-13 | Mamuszka Hannah | Director | P-Purchase | A | Common Stock | 65,789 | 0.76 | 50.0K | 65,789 | — | ↗ |
| 2023-05-16 | Holmlin R. Erik | Director / Officer | P-Purchase | A | Common Stock | 15,000 | 0.64 | 9.6K | 806,474 | — | ↗ |
| 2023-05-12 | Stewart Christopher P. | Officer | P-Purchase | A | Common Stock | 50,000 | 0.67 | 33.4K | 281,373 | — | ↗ |
| 2023-05-12 | OLDAKOWSKI MARK | Officer | F-InKind | D | Common Stock | 41,496 | 0.66 | 27.4K | 297,842 | — | ↗ |
| 2023-05-12 | Holmlin R. Erik | Director / Officer | F-InKind | D | Common Stock | 50,141 | 0.66 | 33.1K | 791,474 | — | ↗ |
| 2023-02-28 | Dixon Jonathan V. | Officer | — | D | Common Stock | 0 | 0.00 | — | 39,270 | — | ↗ |
| 2023-02-15 | Stewart Christopher P. | Officer | A-Award | A | Stock Option (Right to Buy) | 490,000 | 1.63 | 798.7K | 490,000 | — | ↗ |
| 2023-02-15 | OLDAKOWSKI MARK | Officer | A-Award | A | Stock Option (Right to Buy) | 560,000 | 1.63 | 912.8K | 560,000 | — | ↗ |
| 2023-02-15 | Holmlin R. Erik | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,400,000 | 1.63 | 2.28M | 1,400,000 | — | ↗ |
| 2023-02-15 | Chaubey Alka | Officer | A-Award | A | Stock Option (Right to Buy) | 560,000 | 1.63 | 912.8K | 560,000 | — | ↗ |
| 2022-08-15 | Linney Yvonne | Director | M-Exempt | A | Common Stock | 20,000 | 0.38 | 7.6K | 20,000 | — | ↗ |
| 2022-07-07 | BARKER DAVID L | Director | M-Exempt | A | Common Stock | 44,470 | 0.51 | 22.7K | 58,364 | — | ↗ |
| 2022-06-09 | Wong Vincent Jung-Fai | Director | A-Award | A | Stock Option (right to buy) | 164,422 | 0.00 | — | 164,422 | — | ↗ |
| 2022-06-09 | Vuori Kristiina MD | Director | A-Award | A | Stock Option (right to buy) | 164,422 | 0.00 | — | 164,422 | — | ↗ |
| 2022-06-09 | TWOMEY CHRISTOPHER J | Director | A-Award | A | Stock Option (right to buy) | 164,422 | 0.00 | — | 164,422 | — | ↗ |
| 2022-06-09 | Rajkovic Aleksandar | Director | A-Award | A | Stock Option (right to buy) | 164,422 | 0.00 | — | 164,422 | — | ↗ |
| 2022-06-09 | Mamuszka Hannah | Director | A-Award | A | Stock Option (right to buy) | 164,422 | 0.00 | — | 164,422 | — | ↗ |
| 2022-06-09 | Luderer Albert | Director | A-Award | A | Stock Option (right to buy) | 164,422 | 0.00 | — | 164,422 | — | ↗ |
| 2022-06-09 | Linney Yvonne | Director | A-Award | A | Stock Option (right to buy) | 164,422 | 1.62 | 266.4K | 164,422 | — | ↗ |
| 2022-06-09 | BARKER DAVID L | Director | A-Award | A | Stock Option (right to buy) | 164,422 | 1.62 | 266.4K | 164,422 | — | ↗ |
| 2022-05-16 | BARKER DAVID L | Director | P-Purchase | A | Common Stock | 10,000 | 1.60 | 16.0K | 13,894 | — | ↗ |
| 2022-05-13 | Stewart Christopher P. | Officer | M-Exempt | A | Common Stock | 60,000 | 0.56 | 33.6K | 121,579 | — | ↗ |
| 2022-05-12 | OLDAKOWSKI MARK | Officer | F-InKind | D | Common Stock | 41,496 | 1.41 | 58.5K | 216,669 | — | ↗ |
| 2022-05-12 | Holmlin R. Erik | Officer | F-InKind | D | Common Stock | 50,141 | 1.41 | 70.7K | 538,556 | — | ↗ |
| 2022-02-17 | Rajkovic Aleksandar | Director | A-Award | A | Stock Option (right to buy) | 194,986 | 2.04 | 397.8K | 194,986 | — | ↗ |
| 2022-02-15 | Stewart Christopher P. | Officer | A-Award | A | Stock Option (Right to Buy) | 550,000 | 2.18 | 1.20M | 550,000 | — | ↗ |
| 2022-02-15 | Shippy Richard | Officer | A-Award | A | Stock Option (Right to Buy) | 550,000 | 2.18 | 1.20M | 550,000 | — | ↗ |
| 2022-02-15 | Shams Soheil | Officer | A-Award | A | Stock Option (Right to Buy) | 550,000 | 2.18 | 1.20M | 550,000 | — | ↗ |
| 2022-02-15 | OLDAKOWSKI MARK | Officer | A-Award | A | Stock Option (Right to Buy) | 650,000 | 2.18 | 1.42M | 650,000 | — | ↗ |
| 2022-02-15 | Holmlin R. Erik | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,400,000 | 2.18 | 3.05M | 1,400,000 | — | ↗ |
| 2022-02-15 | Chaubey Alka | Officer | A-Award | A | Stock Option (Right to Buy) | 550,000 | 2.18 | 1.20M | 550,000 | — | ↗ |
| 2021-12-31 | Shams Soheil | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-21 | Wong Vincent Jung-Fai | Director | A-Award | A | Stock Option (Right to Buy) | 122,054 | 3.29 | 401.6K | 122,054 | — | ↗ |
| 2021-11-29 | Holmlin R. Erik | Director / Officer | P-Purchase | A | Common Stock | 150 | 3.98 | 597.00 | 5,025 | — | ↗ |
| 2021-11-19 | Stewart Christopher P. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 22,500 | 0.56 | 12.6K | 177,500 | — | ↗ |
| 2021-11-01 | Shams Soheil | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 5.40 | 2.16M | 400,000 | — | ↗ |
| 2021-10-18 | Shams Soheil | Officer | A-Award | A | Common Stock | 5,325,378 | 0.00 | 532.54 | 5,325,378 | — | ↗ |
| 2021-08-17 | Vuori Kristiina MD | Director | A-Award | A | Stock Option (right to buy) | 40,751 | 5.34 | 217.6K | 40,751 | — | ↗ |
| 2021-08-17 | TWOMEY CHRISTOPHER J | Director | A-Award | A | Stock Option (right to buy) | 40,751 | 5.34 | 217.6K | 40,751 | — | ↗ |
| 2021-08-17 | Mamuszka Hannah | Director | A-Award | A | Stock Option (right to buy) | 40,751 | 5.34 | 217.6K | 40,751 | — | ↗ |
| 2021-08-17 | Luderer Albert | Director | A-Award | A | Stock Option (right to buy) | 40,751 | 5.34 | 217.6K | 40,751 | — | ↗ |
| 2021-08-17 | Linney Yvonne | Director | A-Award | A | Stock Option (right to buy) | 40,751 | 5.34 | 217.6K | 40,751 | — | ↗ |
| 2021-08-17 | BARKER DAVID L | Director | A-Award | A | Stock Option (right to buy) | 40,751 | 5.34 | 217.6K | 40,751 | — | ↗ |
| 2021-06-15 | Shippy Richard | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 7.37 | 2.95M | 400,000 | — | ↗ |
| 2021-06-14 | Shippy Richard | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-10 | Vuori Kristiina MD | Director | A-Award | A | Stock Option (right to buy) | 7,528 | 7.64 | 57.5K | 7,528 | — | ↗ |
| 2021-06-10 | TWOMEY CHRISTOPHER J | Director | A-Award | A | Stock Option (right to buy) | 7,528 | 7.64 | 57.5K | 7,528 | — | ↗ |
| 2021-06-10 | Mamuszka Hannah | Director | A-Award | A | Stock Option (right to buy) | 7,528 | 7.64 | 57.5K | 7,528 | — | ↗ |
| 2021-06-10 | Luderer Albert | Director | A-Award | A | Stock Option (right to buy) | 7,528 | 7.64 | 57.5K | 7,528 | — | ↗ |
| 2021-06-10 | Linney Yvonne | Director | A-Award | A | Stock Option (right to buy) | 7,528 | 7.64 | 57.5K | 7,528 | — | ↗ |
| 2021-06-10 | BARKER DAVID L | Director | A-Award | A | Stock Option (right to buy) | 7,528 | 7.64 | 57.5K | 7,528 | — | ↗ |
| 2021-06-01 | Priar Robert J | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-26 | Stewart Christopher P. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 25,000 | 0.56 | 14.0K | 200,000 | — | ↗ |
| 2021-05-12 | OLDAKOWSKI MARK | Officer | A-Award | A | Common Stock | 240,000 | 0.00 | — | 252,086 | — | ↗ |
| 2021-05-12 | Holmlin R. Erik | Director / Officer | A-Award | A | Common Stock | 290,000 | 0.00 | — | 585,191 | — | ↗ |
| 2021-04-01 | Stewart Christopher P. | Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 7.83 | 2.15M | 275,000 | — | ↗ |
| 2021-04-01 | OLDAKOWSKI MARK | Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 7.83 | 2.15M | 275,000 | — | ↗ |
| 2021-04-01 | Holmlin R. Erik | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 775,000 | 7.83 | 6.07M | 775,000 | — | ↗ |
| 2021-04-01 | Chaubey Alka | Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 7.83 | 2.15M | 275,000 | — | ↗ |
| 2021-01-22 | Stewart Christopher P. | Officer | A-Award | A | Common Stock | 8,000 | 6.00 | 48.0K | 8,000 | — | ↗ |
| 2020-09-01 | Stewart Christopher P. | Officer | A-Award | A | Stock Option (Right to Buy) | 225,000 | 0.56 | 126.0K | 225,000 | — | ↗ |
| 2020-09-01 | Chaubey Alka | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 0.56 | 168.3K | 300,000 | — | ↗ |
| 2020-08-31 | Chaubey Alka | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | Vuori Kristiina MD | Director | A-Award | A | Stock Option (right to buy) | 44,470 | 0.51 | 22.7K | 44,470 | — | ↗ |
| 2020-06-30 | TWOMEY CHRISTOPHER J | Director | A-Award | A | Stock Option (Right to Buy) | 44,470 | 0.51 | 22.7K | 44,470 | — | ↗ |
| 2020-06-30 | Mamuszka Hannah | Director | A-Award | A | Stock Option (Right to Buy) | 44,470 | 0.51 | 22.7K | 44,470 | — | ↗ |
| 2020-06-30 | Luderer Albert | Director | A-Award | A | Stock Option (Right to Buy) | 44,470 | 0.51 | 22.7K | 44,470 | — | ↗ |
| 2020-06-30 | Linney Yvonne | Director | A-Award | A | Stock Option (right to buy) | 44,470 | 0.51 | 22.7K | 44,470 | — | ↗ |
| 2020-06-30 | BARKER DAVID L | Director | A-Award | A | Stock Option (right to buy) | 44,470 | 0.51 | 22.7K | 44,470 | — | ↗ |
| 2020-05-04 | Mamuszka Hannah | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-05-04 | Linney Yvonne | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-04-06 | TWOMEY CHRISTOPHER J | Director | A-Award | A | Common Stock Warrants (right to buy) | 45,000 | 0.33 | 14.9K | 45,000 | — | ↗ |
| 2020-02-18 | Robinson Warren | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 1.04 | 124.8K | 120,000 | — | ↗ |
| 2020-02-18 | Holmlin R. Erik | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 290,000 | 1.04 | 301.6K | 290,000 | — | ↗ |
| 2020-02-18 | Borodkin Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 1.04 | 124.8K | 120,000 | — | ↗ |
| 2020-02-18 | Adams Heather | Officer | — | D | Stock Option (right to buy) | 30,000 | 4.25 | 127.5K | 0 | — | ↗ |
| 2019-10-23 | TWOMEY CHRISTOPHER J | Director | A-Award | A | Common Stock | 9,500 | 0.85 | 8.1K | 19,500 | — | ↗ |
| 2019-06-06 | Zhou Quan | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 21,911 | 2.78 | 60.9K | 21,911 | — | ↗ |
| 2019-06-06 | WANG JUNFENG | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 21,911 | 2.78 | 60.9K | 21,911 | — | ↗ |
| 2019-06-06 | Vuori Kristiina MD | Director | A-Award | A | Stock Option (right to buy) | 30,274 | 2.78 | 84.2K | 30,274 | — | ↗ |
| 2019-06-06 | TWOMEY CHRISTOPHER J | Director | A-Award | A | Stock Option (right to buy) | 21,911 | 2.78 | 60.9K | 21,911 | — | ↗ |
| 2019-06-06 | Luderer Albert | Director | A-Award | A | Stock Option (right to buy) | 21,911 | 2.78 | 60.9K | 21,911 | — | ↗ |
| 2019-06-06 | Cai Darren | Director | A-Award | A | Stock Option (right to buy) | 21,911 | 2.78 | 60.9K | 21,911 | — | ↗ |
| 2019-06-06 | BARKER DAVID L | Director | A-Award | A | Stock Option (right to buy) | 21,911 | 2.78 | 60.9K | 21,911 | — | ↗ |
| 2019-03-01 | Ward Michael James | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 4.25 | 255.0K | 60,000 | — | ↗ |
| 2019-03-01 | Robinson Warren | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 4.25 | 255.0K | 60,000 | — | ↗ |
| 2019-03-01 | OLDAKOWSKI MARK | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 4.25 | 255.0K | 60,000 | — | ↗ |
| 2019-03-01 | Holmlin R. Erik | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 145,000 | 4.25 | 616.3K | 145,000 | — | ↗ |
| 2019-01-18 | Borodkin Mark | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,000 | 1.30 | 7.8K | 28,219 | — | ↗ |
| 2018-10-01 | Zhou Quan | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 10,516 | 7.77 | 81.7K | 10,516 | — | ↗ |
| 2018-10-01 | Ward Michael James | Officer | A-Award | A | Stock Option (Right to Buy) | 59,590 | 7.77 | 463.0K | 59,590 | — | ↗ |
| 2018-10-01 | WANG JUNFENG | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 10,516 | 7.77 | 81.7K | 10,516 | — | ↗ |
| 2018-10-01 | TWOMEY CHRISTOPHER J | Director | A-Award | A | Stock Option (Right to Buy) | 10,516 | 7.77 | 81.7K | 10,516 | — | ↗ |
| 2018-10-01 | Robinson Warren | Officer | A-Award | A | Stock Option (Right to Buy) | 64,640 | 7.77 | 502.3K | 64,640 | — | ↗ |
| 2018-10-01 | Luderer Albert | Director | A-Award | A | Stock Option (Right to Buy) | 10,516 | 7.77 | 81.7K | 10,516 | — | ↗ |
| 2018-10-01 | Holmlin R. Erik | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 256,540 | 7.77 | 1.99M | 256,540 | — | ↗ |
| 2018-10-01 | Cao Han PHD | Officer | A-Award | A | Stock Option (Right to Buy) | 23,230 | 7.77 | 180.5K | 23,230 | — | ↗ |
| 2018-10-01 | Cai Darren | Director | A-Award | A | Stock Option (Right to Buy) | 10,516 | 7.77 | 81.7K | 10,516 | — | ↗ |
| 2018-10-01 | Borodkin Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 59,590 | 7.77 | 463.0K | 59,590 | — | ↗ |
| 2018-10-01 | BARKER DAVID L | Director | A-Award | A | Stock Option (Right to Buy) | 10,516 | 7.77 | 81.7K | 10,516 | — | ↗ |
| 2018-09-21 | Wealth Strategy Holding Ltd | 10% Owner | — | D | Warrant | 9,750,000 | 6.13 | 59.72M | 0 | — | ↗ |
| 2018-08-23 | Zhou Quan | Director / 10% Owner | C-Conversion | A | Common Stock | 1,134,000 | 5,000,000.00 | 5.67T | 2,906,915 | — | ↗ |
| 2018-08-23 | WANG JUNFENG | Director / 10% Owner | C-Conversion | D | Series D Convertible Preferred Stock | 6,443,565 | 0.00 | — | 0 | — | ↗ |
| 2018-08-23 | TWOMEY CHRISTOPHER J | Director | P-Purchase | A | Common Stock Warrants (right to buy) | 10,000 | 6.13 | 61.3K | 10,000 | — | ↗ |
| 2018-08-23 | Rosy Shine Ltd | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,134,000 | — | ↗ |
| 2018-08-23 | LC Fund VI, L.P. | 10% Owner | C-Conversion | D | Series D-1 Convertible Preferred Stock | 27,305,708 | 0.00 | — | 0 | — | ↗ |
| 2018-08-23 | Holmlin R. Erik | Director / Officer | P-Purchase | A | Common Stock | 1,630 | 6.13 | 10.0K | 1,630 | — | ↗ |
| 2018-08-23 | Domain Partners VIII, L.P. | 10% Owner | C-Conversion | D | Series D-1 Preferred Stock | 3,682,919 | 0.00 | — | 0 | — | ↗ |
| 2018-08-23 | DP VIII Associates, L.P. | 10% Owner | C-Conversion | A | Common Stock | 2,505 | 4.59 | 11.5K | 6,891 | — | ↗ |
| 2018-08-23 | Cao Han PHD | Officer | C-Conversion | A | Common Stock | 2,433 | 0.00 | — | 112,936 | — | ↗ |
| 2018-08-23 | Borodkin Mark | Officer | P-Purchase | A | Common Stock | 815 | 6.13 | 5.0K | 815 | — | ↗ |
| 2018-08-21 | Zhou Quan | Director / 10% Owner | — | I | Series D Convertible Preferred Stock | 6,443,565 | 0.00 | — | 0 | — | ↗ |
| 2018-08-21 | Wealth Strategy Holding Ltd | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 975,000 | — | ↗ |
| 2018-08-21 | Ward Michael James | Officer | — | D | Stock Option (right to buy) | 1,015 | 64.20 | 65.2K | 0 | — | ↗ |
| 2018-08-21 | WANG JUNFENG | Director / 10% Owner | — | I | Series D-1 Convertible Preferred Stock | 27,305,708 | 0.00 | — | 0 | — | ↗ |
| 2018-08-21 | TWOMEY CHRISTOPHER J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-08-21 | Robinson Warren | Officer | — | D | Stock Option (right to buy) | 29,086 | 1.28 | 37.2K | 0 | — | ↗ |
| 2018-08-21 | Luderer Albert | Director | — | D | Stock Option (right to buy) | 140 | 42.80 | 6.0K | 0 | — | ↗ |
| 2018-08-21 | LC Fund VI, L.P. | 10% Owner | — | I | Series D-1 Convertible Preferred Stock | 27,305,708 | 0.00 | — | 0 | — | ↗ |
| 2018-08-21 | Holmlin R. Erik | Director / Officer | — | D | Stock Option (right to buy) | 273 | 68.48 | 18.7K | 0 | — | ↗ |
| 2018-08-21 | Domain Partners VIII, L.P. | 10% Owner | — | D | Series D-1 Preferred Stock | 86,050 | 0.00 | — | 0 | — | ↗ |
| 2018-08-21 | DP VIII Associates, L.P. | 10% Owner | — | D | Series C Preferred Stock | 941 | 0.00 | — | 0 | — | ↗ |
| 2018-08-21 | DOMAIN ASSOCIATES | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 140 | — | ↗ |
| 2018-08-21 | Cao Han PHD | Officer | — | D | Stock Option (right to buy) | 46 | 291.04 | 13.4K | 0 | — | ↗ |
| 2018-08-21 | Cai Darren | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-08-21 | Borodkin Mark | Officer | — | D | Stock Option (right to buy) | 34,219 | 1.28 | 43.8K | 0 | — | ↗ |
| 2018-08-21 | BARKER DAVID L | Director | — | D | Stock Option (right to buy) | 280 | 64.20 | 18.0K | 0 | — | ↗ |
| 2016-04-04 | Cao Han PHD | Officer | — | D | Series D Convertible Preferred Stock Warrant (Right to Buy) | 10,731,083 | 0.41 | 4.40M | 0 | — | ↗ |
| 2016-03-04 | Zhou Quan | Director / 10% Owner | — | I | Series D Convertible Preferred Stock Warrants (Right to Buy) | 11,263,624 | 0.41 | 4.62M | 0 | — | ↗ |
| 2016-03-04 | WANG JUNFENG | Director / 10% Owner | — | I | Series D Convertible Preferred Stock Warrants (Right to Buy) | 11,263,624 | 0.41 | 4.62M | 0 | — | ↗ |
| 2016-03-04 | LC Fund VI, L.P. | 10% Owner | — | I | Series D Convertible Preferred Stock Warrants (Right to Buy) | 11,263,624 | 0.41 | 4.62M | 0 | — | ↗ |
| 2016-03-04 | Domain Partners VIII, L.P. | 10% Owner | — | D | Warrants to Purchase Series D-1 Preferred Stock | 171,919 | 17.55 | 3.02M | 0 | — | ↗ |
| 2016-03-04 | DP VIII Associates, L.P. | 10% Owner | — | D | Warrants to Purchase Series D-1 Preferred Stock | 1,275 | 17.55 | 22.4K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-340.2K
Shares Outstanding
3.28M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | R. Erik Holmlin, Ph.D. Chief Executive Officer | 600.0K | 192.0K | 40.9K | 140.7K | — | 16.1K | 989.7K | 18.35% | ↗ |
| 2 | 2024 | Mark Oldakowski Chief Operating Officer | 460.0K | 121.8K | 14.8K | 51.7K | — | 15.0K | 663.4K | 10.04% | ↗ |
| 3 | 2024 | Alka Chaubey, Ph.D., FACMG Chief Medical Officer | 459.6K | 121.8K | 14.8K | 51.7K | — | 14.0K | 661.9K | 10.06% | ↗ |
| 4 | 2023 | R. Erik Holmlin, Ph.D. Chief Executive Officer | 598.9K | — | 489.0K | 153.0K | — | 13.7K | 1.25M | 51.17% | ↗ |
| 5 | 2023 | Mark Oldakowski Chief Operating Officer | 459.2K | — | 265.4K | 146.5K | — | 13.7K | 884.8K | 46.55% | ↗ |
| 6 | 2023 | Alka Chaubey, Ph.D., FACMG Chief Medical Officer | 439.2K | — | 265.4K | 146.5K | — | 13.7K | 864.8K | 47.63% | ↗ |
| 7 | 2020 | R. Erik Holmlin, Ph.D. Chief Executive Officer | 376.3K | — | — | 188.5K | 121.5K | 21.3K | 707.6K | 26.64% | ↗ |
| 8 | 2020 | Mark Oldakowski Chief Operating Officer | 288.3K | — | — | 78.0K | 76.4K | 11.4K | 454.1K | 17.18% | ↗ |
| 9 | 2020 | Christopher Stewart Chief Financial Officer | 18.0K | — | — | 210.5K | 23.4K | 451.00 | 252.4K | 83.41% | ↗ |
| 10 | 2019 | R. Erik Holmlin, Ph.D. Chief Executive Officer | 403.6K | — | — | 351.0K | 132.4K | 11.6K | 898.6K | 39.06% | ↗ |
| 11 | 2019 | Mark Oldakowski Chief Operating Officer | 305.3K | — | — | 145.2K | 84.7K | 11.6K | 546.9K | 26.56% | ↗ |
| 12 | 2019 | Warren Robinson Chief Commercial Officer | 305.3K | — | — | 145.2K | 72.7K | 11.6K | 534.8K | 27.16% | ↗ |
| 13 | 2019 | Mike Ward Former Chief Financial Officer | 289.9K | — | — | 145.2K | — | 11.6K | 446.7K | 32.52% | ↗ |
| 14 | 2019 | Christopher Stewart Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 15 | 2018 | R. Erik Holmlin, Ph.D. Chief Executive Officer | 390.0K | — | — | 1.99M | 132.6K | 11.4K | 2.53M | 78.87% | ↗ |
| 16 | 2018 | Warren Robinson Chief Commercial Officer | 295.0K | — | — | 502.3K | 88.8K | 11.4K | 897.4K | 55.97% | ↗ |
| 17 | 2018 | Mike Ward Former Chief Financial Officer | 289.1K | — | — | 463.0K | 78.2K | 11.4K | 841.7K | 55.01% | ↗ |
| 18 | 2018 | Mark Oldakowski Chief Operating Officer | 295.0K | — | — | 258.7K | 47.4K | 11.4K | 612.4K | 42.24% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert Erik Holmlin | President, CEO, Principal Financial Officer & Director | 1M | — |
| Alka Chaubey FACMG | Chief Medical Officer | 734.2K | — |
| Mark Oldakowski | Chief Operating Officer | 734.2K | male |
| Mark Adamchak | VP of Accounting, Principal Accounting Officer & Controller | — | male |
| Jonathan Dixon | General Counsel & Secretary | — | male |
| Cory Kreeck | Global Head of People Operations | — | male |
| Donna Polizio | Global Head of Market Access | — | female |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BNGO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
